Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Association between undervaccination with diphtheria, tetanus toxoids, and acellular pertussis (DTaP) vaccine and risk of pertussis infection in children 3 to 36 months of age.

Glanz JM, Narwaney KJ, Newcomer SR, Daley MF, Hambidge SJ, Rowhani-Rahbar A, Lee GM, Nelson JC, Naleway AL, Nordin JD, Lugg MM, Weintraub ES.

JAMA Pediatr. 2013 Nov;167(11):1060-4. doi: 10.1001/jamapediatrics.2013.2353.

PMID:
24019039
2.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
3.

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group.

Pediatrics. 2001 Nov;108(5):E81.

PMID:
11694665
4.

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW.

JAMA. 2012 Nov 28;308(20):2126-32. doi: 10.1001/jama.2012.14939.

PMID:
23188029
5.

Effects of a minimum interval immunization schedule for diphtheria and tetanus toxoids and acellular pertussis vaccination during a pertussis outbreak.

Bronson-Lowe D, Anderson SM.

Arch Pediatr Adolesc Med. 2009 May;163(5):417-21. doi: 10.1001/archpediatrics.2009.53.

PMID:
19414686
6.

Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.

Heininger U, Cherry JD, Stehr K, Schmitt-Grohé S, Uberall M, Laussucq S, Eckhardt T, Meyer M, Gornbein J.

Pediatrics. 1998 Sep;102(3 Pt 1):546-53.

PMID:
9738175
7.

A population-based cohort study of undervaccination in 8 managed care organizations across the United States.

Glanz JM, Newcomer SR, Narwaney KJ, Hambidge SJ, Daley MF, Wagner NM, McClure DL, Xu S, Rowhani-Rahbar A, Lee GM, Nelson JC, Donahue JG, Naleway AL, Nordin JD, Lugg MM, Weintraub ES.

JAMA Pediatr. 2013 Mar 1;167(3):274-81. doi: 10.1001/jamapediatrics.2013.502.

PMID:
23338829
8.

A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.

Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, uberall M, Laussucq S, Eckhardt T, Meyer M, Engelhardt R, Christenson P.

Pediatrics. 1998 Jan;101(1 Pt 1):1-11.

PMID:
9417143
9.

Waning protection after fifth dose of acellular pertussis vaccine in children.

Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R.

N Engl J Med. 2012 Sep 13;367(11):1012-9. doi: 10.1056/NEJMoa1200850.

11.

Duration of protection after first dose of acellular pertussis vaccine in infants.

Quinn HE, Snelling TL, Macartney KK, McIntyre PB.

Pediatrics. 2014 Mar;133(3):e513-9. doi: 10.1542/peds.2013-3181. Epub 2014 Feb 10.

12.

Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.

Pichichero ME, Edwards KM, Anderson EL, Rennels MB, Englund JA, Yerg DE, Blackwelder WC, Jansen DL, Meade BD.

Pediatrics. 2000 Jan;105(1):e11.

PMID:
10617748
13.

Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers.

Klein NP, Bartlett J, Fireman B, Rowhani-Rahbar A, Baxter R.

Pediatrics. 2013 Jun;131(6):e1716-22. doi: 10.1542/peds.2012-3836. Epub 2013 May 20.

14.

Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

[No authors listed]

MMWR Recomm Rep. 1997 Mar 28;46(RR-7):1-25. Erratum in: MMWR Morb Mortal Wkly Rep 1997 Aug 1;46(30):706.

15.

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.

Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD.

Pediatrics. 1997 Nov;100(5):772-88.

PMID:
9346976
16.

Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).

Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, Mijalski CM, Tiwari T, Weston EJ, Cohn AC, Srivastava PU, Moran JS, Schwartz B, Murphy TV; Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34.

17.

Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.

America Academy of Pediatrics Commitee on Infectious Diseases.

Pediatrics. 2006 Mar;117(3):965-78. Epub 2005 Dec 28.

PMID:
16382131
18.

Lack of association between acellular pertussis vaccine and seizures in early childhood.

Huang WT, Gargiullo PM, Broder KR, Weintraub ES, Iskander JK, Klein NP, Baggs JM; Vaccine Safety Datalink Team.

Pediatrics. 2010 Aug;126(2):263-9. doi: 10.1542/peds.2009-1496. Epub 2010 Jul 19.

PMID:
20643726
20.

Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.

Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR.

J Pediatr. 2006 Nov;149(5):603-610.

PMID:
17095328
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk